Evidence map›Paper›PMID 32330433›Full record

Trial reportJornal de pediatria

Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial.

Adriana Rocha Brito, Giselle de Paula Teixeira Vairo, Ana Paula Botelho Henriques Dias, Beni Olej, Osvaldo José Moreira Nascimento, Marcio Moacyr Vasconcelos

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Jornal de pediatria. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Pharmacotherapy for the core symptoms of autism spectrum disorder.Journal of Zhejiang University. Science. B · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Adriana Rocha BritoUniversidade Federal Fluminense (UFF), Departamento Materno-Infantil, Niterói, RJ, Brazil.
Giselle de Paula Teixeira VairoUniversidade Federal Fluminense (UFF), Departamento Materno-Infantil, Niterói, RJ, Brazil.
Ana Paula Botelho Henriques DiasUniversidade Federal Fluminense (UFF), Departamento Materno-Infantil, Niterói, RJ, Brazil.
Beni OlejUniversidade Federal Fluminense (UFF), Departamento de Medicina Clínica, Niterói, RJ, Brazil.
Osvaldo José Moreira NascimentoUniversidade Federal Fluminense (UFF), Departamento de Medicina Clínica, Niterói, RJ, Brazil.
Marcio Moacyr VasconcelosUniversidade Federal Fluminense (UFF), Departamento Materno-Infantil, Niterói, RJ, Brazil. Electronic address: mmdvascon@gmail.com.
Universidade Federal Fluminense · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the effect of prednisolone on language in children with autism spectrum disorder. This study is based upon two hypotheses: autism etiology may be closely related to neuroinflammation; and, an effective treatment should restore the individual's language skills.

methodThis is a prospective, double-blinded, randomized, placebo-controlled clinical trial, carried out in a federal university hospital. The initial patient sample consisted of 40 subjects, which were randomized into two parallel groups. Inclusion criteria were: male gender, 3-7 years of age, and meeting the Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) diagnostic criteria. The final sample consisted of 38 patients, of whom 20 were randomized to the placebo group and 18 to the active group. The latter received prednisolone for 24 weeks, at an initial dose of 1mg/kg/day and a tapering dose from the ninth week onward. Language was measured on four occasions over a 12-month period by applying two Brazilian tools: the Language Development Assessment (ADL) and the Child Language Test in Phonology, Vocabulary, Fluency, and Pragmatics (ABFW).

resultsThe side effects were mild: two patients had hypertension, five had hyperglycemia, and two had varicella. Prednisolone increased the global ADL score in children younger than 5 years of age who had developmental regression (p=0.0057). The ABFW's total of communicative acts also responded favorably in those participants with regression (p=0.054). The ABFW's total of vocal acts showed the most significant results, especially in children younger than 5 years (p=0.004, power=0.913).

conclusionsThe benefit of prednisolone for language scores was more evident in participants who were younger than five years, with a history of developmental regression, but the trial's low dose may have limited this benefit. The observed side effects do not contraindicate corticosteroid use in autism.

Indexed as

Autism Spectrum DisorderAutistic DisorderBrazilChildHumansMalePrednisoloneProspective StudiesPrednisoloneAutismAutistic disorderCorticosteroidsImmunomodulationLanguage

Identifiers

PMID32330433
PMCPMC9432069
OpenAlexW3020536228

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.